According to cholesterol guidelines, adults aged 40-75 with diabetes, an LDL-C level of 70-189 mg/dL, and no clinical ASCVD should do what?

According to cholesterol guidelines, adults aged 40-75 with diabetes, an LDL-C level of 70-189 mg/dL, and no clinical ASCVD should do what?

• A. Start aspirin therapy
• B. Close monitoring without statin
• C. Repeat lipid panel in 6 months
• D. Start a moderate-intensity statin

Answer: (D)

In adults aged 40–75 with diabetes and an LDL-C between 70 and 189 mg/dL who have no clinical ASCVD, the approach is to start a moderate-intensity statin to reduce future cardiovascular events. Diabetes itself elevates ASCVD risk, and LDL in this range signals that lipid-lowering therapy can provide meaningful benefit. Moderate-intensity statins typically lower LDL-C by roughly 30–49% and include options like atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg, or pravastatin 40–80 mg. This level of therapy strikes a balance between reducing risk and tolerability for most patients in this group. Close monitoring without statin would miss a proven preventive strategy, and repeating a lipid panel alone without initiating therapy doesn’t address the underlying risk. Routine aspirin for primary prevention is generally not recommended due to bleeding risk, unless there are very high ASCVD risk factors and low bleeding risk, which isn’t specified here. Therefore starting a moderate-intensity statin is the best, guideline-based choice.

In adults aged 40–75 with diabetes and an LDL-C between 70 and 189 mg/dL who have no clinical ASCVD, the approach is to start a moderate-intensity statin to reduce future cardiovascular events. Diabetes itself elevates ASCVD risk, and LDL in this range signals that lipid-lowering therapy can provide meaningful benefit. Moderate-intensity statins typically lower LDL-C by roughly 30–49% and include options like atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg, or pravastatin 40–80 mg. This level of therapy strikes a balance between reducing risk and tolerability for most patients in this group.

Close monitoring without statin would miss a proven preventive strategy, and repeating a lipid panel alone without initiating therapy doesn’t address the underlying risk. Routine aspirin for primary prevention is generally not recommended due to bleeding risk, unless there are very high ASCVD risk factors and low bleeding risk, which isn’t specified here. Therefore starting a moderate-intensity statin is the best, guideline-based choice.